What are the key mechanisms of CV benefit of novel diabetes drugs?

What are the key mechanisms of CV benefit of novel diabetes drugs
    10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME
    • Overview

      Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

    • Educational information

      This video was recorded during a two-day expert meeting among cardiologists and endocrinologists/internists, focussing on the topic of 'Exploring the role of GLP-1 RA in the management of CVD & T2DM'. This video reflects the discussion in the second of 5 sessions.

    • Faculty

      Prof. Lina Badimon - cardiologist, Hospital Santa Creu and San Pau, Barcelona, Spain

      Prof. Jochen Seufert - endocrinologist, Universitätsklinikum, Freiburg, Germany

      Prof. Naveed Sattar -endocrinologist, University of Glasgow, United Kingdom

    • Disclosures

      This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

    Facebook Comments


    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free